[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653904":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":24,"interventions":31,"overallOfficials":17,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":17,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":17,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":17,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":17,"overallStatus":81,"whyStopped":17,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University of Kentucky","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"Medication Adherence Rate","Percentage of prescribed hepatitis C medication doses taken during the treatment period, measured using the cellular-connected smart pillbox.","12 Weeks After Treatment Initiation",{"measure":14,"description":15,"timeFrame":16},"Sustained Virologic Response at 4 Weeks (SVR4)","Percentage of participants who achieved a sustained virologic response, indicating hepatitis C cure, at 4 weeks after completion of treatment.","4 Weeks after completion of treatment",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE",[25],{"label":26,"type":27,"description":28,"interventionNames":29},"Medication in Hand","EXPERIMENTAL","Participants will receive hepatitis C treatment during the emergency department visit, along with medication adherence support using a cellular-connected smart pillbox, an artificial intelligence-powered virtual agent, and community health worker support. Participants will be followed through treatment completion and follow-up testing.",[30],"Drug: Epclusa (sofosbuvir and velpatasvir)",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":17},"DRUG","Epclusa (sofosbuvir and velpatasvir)","Participants who test positive for hepatitis C will receive sofosbuvir\u002Fvelpatasvir treatment before discharge from the Emergency Department. The first month of medication will be provided by the study, with subsequent treatment coordinated through the clinical team and specialty pharmacy.",[26],[38],{"name":39,"role":40,"phone":41,"phoneExt":17,"email":42},"Ronda Shea","CONTACT","859-323-5212","ronda.petrey@uky.edu",[44],{"facility":5,"status":17,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Lexington","Kentucky","40506","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-84.47772,37.98869,{"lat":54,"lon":53},[57],{"name":58,"role":40,"phone":17,"phoneExt":17,"email":59},"Patrick Grace","patrick.grace@uky.edu",{"type":61,"investigatorFullName":58,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Associate Professor","100653904","phase-4-ai-powered-hepatitis-c-single-encounter-test-and-treat-100653904",false,"NCT07793643","AI-Powered Hepatitis C Single-Encounter Test-and-Treat","Inclusion Criteria:\n\n* Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening\n* Patients to be discharged from the ED or ED Observational units\n\nExclusion Criteria:\n\n* Capacity to Consent\n* Emergency Severity Index (ESI) Level one (high acuity patients)\n* Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.)\n* Known clinical evidence of cirrhosis (egliver nodularity and\u002For splenomegaly on imaging, platelet count \\\u003C150,000\u002Fm3, etc.)\n* Known prior liver biopsy showing cirrhosis\n\n  •Pregnancy\n* Known or suspected Hepatocellular carcinoma\n* Followed by hospice or transplant, have a life expectancy \\\u003C 1 year\n* Chronic Kidney Disease (CKD) or on dialysis\n* Allergy to study medications\n* Patients admitted to the hospital","ALL","22 Years","65 Years",{"count":73,"type":74},35,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.",[80],"HEPATITIS C (HCV)","NOT_YET_RECRUITING","2026-08-26",{"date":84,"type":85},"2026-08-28","ACTUAL",{"date":87,"type":74},"2026-12-01",{"date":89,"type":74},"2028-09-01",{"name":58,"class":6},1]